| 92738-4 | Oxysterols Pnl Bld | 3 |
| 92739-2 | CTX Pnl DBS | 3 |
| 92740-0 | Oxysterols Pnl SerPl | 4 |
| 92741-8 | Oxysterols Pnl DBS | 3 |
| 92743-4 | HepSplenMeg Pnl SerPl | 7 |
| 92744-2 | HepSplenMeg Pnl Bld | 7 |
| 92745-9 | HepSplenMeg Pnl DBS | 8 |
| 92746-7 | CTX Pnl SerPl | 3 |
| 92789-7 | GP Bld Culture Pnl Bld Pos NAA+probe | 27 |
| 92805-1 | Bld fungal path panel Bld Pos NAA+probe | 16 |
| 92815-0 | Borrelia af+burg+gari IgG Pnl Ser+CSF | 6 |
| 92820-0 | Glucose p glucagon stimulation Pnl SerPl | 5 |
| 92847-3 | HSV 1 + 2 + VZV DNA Pnl Bld NAA+probe | 4 |
| 92849-9 | HSV 1 + 2 + VZV DNA Pnl CSF NAA+probe | 4 |
| 92852-3 | HAdV + HBoV DNA Pnl Lower resp NAA+probe | 3 |
| 92853-1 | HAdV + HBoV DNA Pnl Upper resp NAA+probe | 3 |
| 92859-8 | C pn + M pn DNA Pnl Lower resp NAA+probe | 3 |
| 92860-6 | C pn + M pn DNA Pnl Upper resp NAA+probe | 3 |
| 92861-4 | HSV 1 + 2 + VZV DNA Pnl Skin NAA+probe | 4 |
| 92862-2 | HSV 1 + 2 + VZV DNA Pnl SerPl NAA+probe | 4 |
| 92863-0 | HSV 1+2 DNA Pnl Skin NAA+probe | 3 |
| 92864-8 | HSV 1+2 DNA Pnl Lower resp NAA+probe | 3 |
| 92865-5 | HSV 1+2 DNA Pnl CSF NAA+probe | 3 |
| 92866-3 | HSV 1+2 DNA Pnl SerPl NAA+probe | 3 |
| 92867-1 | HSV 1+2 DNA Pnl Bld NAA+probe | 3 |
| 92868-9 | HSV 1+2 DNA Pnl Upper resp NAA+probe | 3 |
| 92869-7 | HSV 1+2 DNA Pnl BAL NAA+probe | 3 |
| 92876-2 | 4 HCoVs + HPIV1-4 RNA Pnl LowResp NAA+Pr | 3 |
| 92877-0 | 4 HCoVs + HPIV1-4 RNA Pnl Up resp NAA+pr | 3 |
| 92880-4 | hMPV + RSV RNA Pnl Lower resp NAA+probe | 3 |
| 92881-2 | hMPV + RSV RNA Pnl Upper resp NAA+probe | 3 |
| 92882-0 | FLUAV + FLUBV Pnl Upper resp NAA+probe | 3 |
| 92889-5 | Chronic hepatitis diff Pnl SerPl | 6 |
| 92890-3 | HAV+HBV+HCV immunity +or expos Pnl SerPl | 7 |
| 92898-6 | HBV core + surf + little e Pnl SerPl | 8 |
| 92901-8 | NIP fet aneu microdel pnl Plas.cfDNA Seq | 11 |
| 92908-3 | Functional limitation in range of motion:-:RptPeriod:^Patient:-:CMS Assessment | 56 |
| 92929-9 | MeV + MuV + RUBV IgG Pnl SerPl-aCnc | 4 |
| 92938-0 | Catecholamines 3 Pnl Ur | 10 |
| 92958-8 | Resp path DNA+RNA Pnl L Resp NAA+non-prb | 66 |
| 93000-8 | PhenX body proportions proto | 7 |
| 93016-4 | SARA panel | 18 |
| 93022-2 | Multiple myeloma MRD Pnl Mar FC | 13 |
| 93025-5 | Protocol for Responding to and Assessing Patients' Assets, Risks, and Experiences:-:Pt:^Patient:-:PRAPARE | 6 |
| 93039-6 | Optional additional questions:-:Pt:^Patient:-:PRAPARE | 4 |
| 93040-4 | Social and emotional health:-:Pt:^Patient:-:PRAPARE | 2 |
| 93041-2 | Money and resources:-:Pt:^Patient:-:PRAPARE | 6 |
| 93042-0 | Family and home:-:Pt:^Patient:-:PRAPARE | 4 |
| 93043-8 | Personal characteristics:-:Pt:^Patient:-:PRAPARE | 5 |
| 93049-5 | MDS v3.0 - RAI v1.17.2 - Correction request - SP, SD:-:RptPeriod:^Patient:-:CMS Assessment | 16 |